Visiting professor, doctoral supervisor at Macau University of Science and Technology. Professor, doctoral supervisor and Master's degree supervisor in Southern Medical University & Medical College of South China University of Technology.
•Specialties: Rheumatology
•Clinical Interests: Dedicated to diagnosis and treatment of rheumatic diseases, especially focusing on connective tissue disease-associated lung involvement, including interstitial lung disease and pulmonary arterial hypertension.
•Bio: Being Vice director and professor of department of Rheumatology in 3rd Affiliated hospital Sun Yat-Sen University of Medical Science between 1995 and 2002. Has begun to work in Guangdong Provincial People’s hospital as director since 2003 and set up the department of Rheumatology which ranks among the top in South China.
•Education: Graduated from Jiangxi Medical College in 1982. Accomplished research and attending doctor program in Department of Rheumatology and Immunology, Renji Hospital, Shanghai Second Medical University in 1991. Accomplished post-doctoral fellowship between 1999 and 2002 in department of Rheumatology in Royal Perth Hospital, Australia and The John P. Robarts Research Institute, University of Western Ontario, Canada.
•Awards and Honors: In the past five years, received two National Natural Science Foundation grants, two grants from the Guangdong Natural Science Foundation and one from the Guangzhou Science and Technology Commission, and served as subunit leader of the National Thirteenth-Five Precision Medicine Key Research (Sjogren and interstitial lung disease). Invited to make speeches at the European Annual Congress of Rheumatology and many national rheumatology conferences.
•Professional memberships: Vice chairman of Chinese Association of Rheumatology and Immunology Physicians; Vice chairman of Chinese Rheumatology Center Alliance; Formal Chairman of Rheumatology and Immunology branch of Guangdong Medical Doctor Association; Vice director of Guangdong Medical Association of Rheumatology and immunology; Director of Guangdong-Hong Kong-Macao Greater Bay Area Alliance of Rheumatologist.
Editor of Chinese Journal of Rheumatology, Chinese Journal of Allergy & Clinical Immunology, The Journal of Evidence-Based Medicine; Corresponding editor of Chinese Journal of Internal Medicine, National Medical Journal of China; Deputy editor of the Chinese version of Annals of the Rheumatic Diseases. Evaluation expert of NSFC and Guangdong Natural Science Foundation.
•Publications:(*Corresponding author)
1.Haobo Li, Chaocheng Wu, FuZhu, Guangfeng Zhang, YueshengXie, Yan Cui, Guangfu Dong, Xiao Zhang*. –fibrotic effect of Iguratimod on pulmonary fibrosis by inhibiting the fibroblast- to-myofibroblast transition[J].Advances in medical Sciences.2020,23:65(2):338-347
2.Lei Y, Zhang X,* Lin H, Feng Y, Wang J, Luo R. The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis[J]. Modern rheumatology, 2020:1-11.
3.Wang J, Li M, Wang Q, Zhang X, Qian J, Zhao J, Xu D, Tian Z, Wei W, Zuo X, Zhang M, Zhu P, Ye S, Zhang W, Zheng Y, Qi W, Li Y, Zhang Z, Ding F, Gu J, Liu Y, Wang Y, Zhao Y, Zeng X. Pulmonary arterial hypertension associated with primary Sjogren's syndrome: a multi-centre cohort study from China[J]. The European respiratory journal, 2020.
4.Xu T, Zhang G, Lin H, Xie Y, Feng Y, Zhang X, Dong G. Clinical Characteristics and Risk Factors of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: a Systematic Review and Meta-Analysis Based on Observational Studies[J]. Clinical reviews in allergy & immunology, 2019.
5.Zhang G, Zhang X, Chai Y, Zang S, Shi Y, Wu H. Rapid induction of clinical remission by immunoadsorption for refractory lupus retinopathy complicated with life-threatening neuropsychiatric lupus[J]. Annals of the rheumatic diseases, 2020,79(2):302-304.
6.Wu Chaochen, Lin Haobo, Zhang Xiao*. Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3)[J]. International immunopharmacology, 2019, 74: 105700.
7.Fangfang Sun, Yunxia Lei, Wanlong Wu, Li Guo, Kaiwen Wang, Zhiwei Chen, Wenwen Xu1, Xiaodong Wang, Ting Li, Xiao Zhang*, Shuang Ye.Two distinct clinical phenotypes of pulmonary arterial hypertension secondary to systemic lupus erythematosus[J]. Annals of the rheumatic diseases, 2019, 78(1): 148-150.
8.Junyan Qian, Mengtao Li, Xiao Zhang, Qian Wang, Jiuliang Zhao, Zhuang Tian, Wei Wei, XiaoxiaZuo, Miaojia Zhang, Ping Zhu, Shuang Ye, Wei Zhang, Yi Zheng, Wufang Qi, Yang Li, Zhuoli Zhang, Feng Ding, JieruoGu, Yi Liu, Yanhong Wang, XiaofengZeng.Long-Term Prognosis of Patients with Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: CSTAR-PAH Cohort Study[J]. European Respiratory Journal, 2019: 1800081.
9.Hua Xiao,Guang‐feng Zhang,Xiang‐ping Liao,Xiao‐jie Li,Jian Zhang,Haobo Lin,Zhe Chen ,Xiao Zhang* .Anti‐fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis‐associated interstitial lung disease[J]. International journal of rheumatic diseases.2018, 21(2): 477-486.
10.Liu Y, Zhan F, Zhang X*, Shu D L. Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus[J]. Experimental and therapeutic medicine, 2018, 15(1): 585-591.
